AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Five dose levels of monoclonal antibody melanoma vaccine compared.
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- Researchers report the results of a phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside in a recent issue of the journal Vaccine.
According to a study from the United States, "In previous studies, we showed that immunization with 2.5 mg of BEC2, an anti-idiotypic MAb that mimics GD3 ganglioside, can induce antibodies against GD3 in approximately 25% of patients. In this trial, 50 melanoma patients at high risk for recurrence were randomly assigned to one of the five BEC2 dose levels (2.5 mcg-10 mg) to determine if lower or higher BEC2 doses are more immunogenic. We also tested whether prolonged booster immunizations can enhance the anti-GD3 antibody response."
"All patients developed detectable IgG against BEC2 except for one patient at the lowest BEC2 dose level," reported Paul B. Chapman and colleagues at the Memorial Sloan-Kettering Cancer Center in New York. "Six patients developed detectable antibody responses to GD3, all of them at the lower three dose levels of BEC2. We conclude that high doses of BEC2 are not necessary to induce anti-GD3 ...
- Researchers at Shizuoka Cancer Center release new data on neutropenia...
- Newspaper article from: Blood Weekly July 16, 2009 700+ words
...pegfilgrastim dose cohort (dose levels of 30, 60 or 100 microg...was observed at all dose levels," wrote N. Yamamoto...colleagues, Shizuoka Cancer Center. The researchers concluded...Yamamoto, Shizuoka Cancer Center, Division of Thoracic...
- Scientists at Harvard University, Harvard Cancer Center target solid cancer...
- Newspaper article from: Blood Weekly January 29, 2009 700+ words
...total of 33 patients were evaluated at 7 dose levels ranging from 0.27 to 3.20 mg/m...colleagues, Harvard University, Harvard Cancer Center (see also Solid Cancer Therapy...General Hospital, Dana-Farber, Harvard Cancer Center, Harvard Medical School, Boston...
- New non-small cell lung cancer therapy study findings recently were published...
- Newspaper article from: Cancer Weekly September 15, 2009 700+ words
...area under the curve: AUC) at four dose levels: 800/4 (level 1), 1000/4 (level...H. Kim and colleagues, National Cancer Center Hospital East. The researchers concluded...information, contact Y.H. Kim, National Cancer Center Hospital East, Division of Thoracic...
- Top Malaysian Cancer Center Begins Treatments Using World's Most Versatile and...
- Press release article from: PR Newswire July 20, 2006 700+ words
NILAI, Malaysia, July 20 /PRNewswire/ -- A leading cancer center in Malaysia has begun offering patients state-of-the...reducing doses to adjacent critical structures. We can reach dose levels with the Trilogy that we simply couldn't before and our...
- Memorial Sloan-Kettering Cancer Center Phase I/II Study Concludes SuperGen's...
- Press release article from: PR Newswire November 13, 2001 700+ words
...associate attending physician at Memorial Sloan-Kettering Cancer Center in New York City, and the study's lead investigator...enrolled and treated with a fixed dose of Nipent and one of two dose levels of cyclophosphamide. The median number of earlier treatment...
- ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed...
- Press release article from: PR Newswire April 23, 2009 700+ words
...inhibitor, demonstrated potent antiviral activity at all dose levels and was well tolerated in a Phase Ib study in which patients...treatment (Day 4) exceeding 2 log10 (>99%) at all dose levels. At 200 mg bid (twice-daily), the median viral load...
- Regeneron Reports Positive Phase 1 Data for the VEGF Trap in Age-Related...
- Press release article from: Business Wire May 1, 2006 700+ words
...meeting its primary endpoints of safety and tolerability at all dose levels, the VEGF Trap demonstrated positive preliminary efficacy...doses of the VEGF Trap were generally well tolerated at all dose levels tested (0.05 to 4 mg), with no systemic or serious adverse...
- Phase II efficacy study looking at a single-dose of one of three dose levels of...
- Magazine article from: Journal of Drugs in Dermatology July 1, 2009 700+ words
Phase II Efficacy Study Looking at a Single-Dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-Type Psoriasis Sponsored by Novartis. This is an exploratory, 4-arm, parallel...
Source: HighBeam Research, Five dose levels of monoclonal antibody melanoma vaccine compared.